Literature DB >> 32240612

Sustainable care for children with cancer: a Lancet Oncology Commission.

Rifat Atun1, Nickhill Bhakta2, Avram Denburg3, A Lindsay Frazier4, Paola Friedrich2, Sumit Gupta3, Catherine G Lam2, Zachary J Ward5, Jennifer M Yeh6, Claudia Allemani7, Michel P Coleman7, Veronica Di Carlo7, Eva Loucaides8, Elizabeth Fitchett9, Fabio Girardi7, Susan E Horton10, Freddie Bray11, Eva Steliarova-Foucher11, Richard Sullivan12, Joanne F Aitken13, Shripad Banavali14, Agnes Binagwaho15, Patricia Alcasabas16, Federico Antillon17, Ramandeep S Arora18, Ronald D Barr19, Eric Bouffet20, Julia Challinor21, Soad Fuentes-Alabi22, Thomas Gross23, Lars Hagander24, Ruth I Hoffman25, Cristian Herrera26, Tezer Kutluk27, Karen J Marcus28, Claude Moreira29, Kathy Pritchard-Jones9, Oscar Ramirez30, Lorna Renner31, Leslie L Robison32, Jaime Shalkow33, Lillian Sung3, Allen Yeoh34, Carlos Rodriguez-Galindo35.   

Abstract

We estimate that there will be 13·7 million new cases of childhood cancer globally between 2020 and 2050. At current levels of health system performance (including access and referral), 6·1 million (44·9%) of these children will be undiagnosed. Between 2020 and 2050, 11·1 million children will die from cancer if no additional investments are made to improve access to health-care services or childhood cancer treatment. Of this total, 9·3 million children (84·1%) will be in low-income and lower-middle-income countries. This burden could be vastly reduced with new funding to scale up cost-effective interventions. Simultaneous comprehensive scale-up of interventions could avert 6·2 million deaths in children with cancer in this period, more than half (56·1%) of the total number of deaths otherwise projected. Taking excess mortality risk into consideration, this reduction in the number of deaths is projected to produce a gain of 318 million life-years. In addition, the global lifetime productivity gains of US$2580 billion in 2020-50 would be four times greater than the cumulative treatment costs of $594 billion, producing a net benefit of $1986 billion on the global investment: a net return of $3 for every $1 invested. In sum, the burden of childhood cancer, which has been grossly underestimated in the past, can be effectively diminished to realise massive health and economic benefits and to avert millions of needless deaths.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32240612     DOI: 10.1016/S1470-2045(20)30022-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  31 in total

Review 1.  The Lancet Commission on diagnostics: transforming access to diagnostics.

Authors:  Kenneth A Fleming; Susan Horton; Michael L Wilson; Rifat Atun; Kristen DeStigter; John Flanigan; Shahin Sayed; Pierrick Adam; Bertha Aguilar; Savvas Andronikou; Catharina Boehme; William Cherniak; Annie Ny Cheung; Bernice Dahn; Lluis Donoso-Bach; Tania Douglas; Patricia Garcia; Sarwat Hussain; Hari S Iyer; Mikashmi Kohli; Alain B Labrique; Lai-Meng Looi; John G Meara; John Nkengasong; Madhukar Pai; Kara-Lee Pool; Kaushik Ramaiya; Lee Schroeder; Devanshi Shah; Richard Sullivan; Bien-Soo Tan; Kamini Walia
Journal:  Lancet       Date:  2021-10-06       Impact factor: 79.321

2.  International Comparisons of Clinical Demographics and Outcomes in the International Society of Pediatric Oncology Wilms Tumor 2001 Trial and Study.

Authors:  Joaquim Caetano de Aguirre-Neto; Beatriz de Camargo; Harm van Tinteren; Christophe Bergeron; Jesper Brok; Gema Ramírez-Villar; Arnauld Verschuur; Rhoikos Furtwängler; Lisa Howell; Daniel Saunders; Oystein Olsen; Aurore Coulomb; Christian Vokuhl; Jan Godzinski; Anne M Smets; Gordan M Vujanic; Marry M van den Heuvel-Eibrink; Norbert Graf; Kathy Pritchard-Jones
Journal:  JCO Glob Oncol       Date:  2022-05

3.  Clinical trials of stem cell-based therapies for pediatric diseases: a comprehensive analysis of trials registered on ClinicalTrials.gov and the ICTRP portal site.

Authors:  Yinwen Ji; Chuan Hu; Zuxing Chen; Ying Li; Jiayong Dai; Jin Zhang; Qiang Shu
Journal:  Stem Cell Res Ther       Date:  2022-07-15       Impact factor: 8.079

4.  Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa.

Authors:  Nmazuo W Ozuah; Joseph Lubega; Carl E Allen; Nader Kim El-Mallawany
Journal:  Blood Adv       Date:  2020-08-25

5.  Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis.

Authors:  Zachary J Ward; Andrew M Scott; Hedvig Hricak; Rifat Atun
Journal:  Lancet Oncol       Date:  2021-03       Impact factor: 41.316

6.  Increasing Access to Imaging for Addressing the Global Cancer Epidemic.

Authors:  Hedvig Hricak; Ada Muellner; Zachary J Ward; Rifat Atun; May Abdel-Wahab; Andrew M Scott
Journal:  Radiology       Date:  2021-09-28       Impact factor: 11.105

Review 7.  Medical imaging and nuclear medicine: a Lancet Oncology Commission.

Authors:  Hedvig Hricak; May Abdel-Wahab; Rifat Atun; Miriam Mikhail Lette; Diana Paez; James A Brink; Lluís Donoso-Bach; Guy Frija; Monika Hierath; Ola Holmberg; Pek-Lan Khong; Jason S Lewis; Geraldine McGinty; Wim J G Oyen; Lawrence N Shulman; Zachary J Ward; Andrew M Scott
Journal:  Lancet Oncol       Date:  2021-03-04       Impact factor: 41.316

8.  Survivor and parent engagement in childhood cancer treatment in Iran.

Authors:  Shirin Ahmadnia; Atena Kamel Ghalibaf; Saba Kamkar; Zahra Mohamadzadeh; Mithra Ghalibafian
Journal:  Ecancermedicalscience       Date:  2021-04-19

9.  Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis.

Authors:  Karolina Strzebonska; Mateusz T Wasylewski; Lucja Zaborowska; Maciej Polak; Emilia Slugocka; Jakub Stras; Mateusz Blukacz; Bishal Gyawali; Marcin Waligora
Journal:  Target Oncol       Date:  2021-06-10       Impact factor: 4.493

10.  Medical Cost of Cancer Care for Privately Insured Children in Chile.

Authors:  Florencia Borrescio-Higa; Nieves Valdés
Journal:  Int J Environ Res Public Health       Date:  2021-06-23       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.